2026-526116-36-00招募中1 期
A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 15
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Jenny Amaya
Scientific
Pliant Therapeutics Inc.
研究点 (7)
Loading locations...
相似试验
招募中
1 期
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumorsLocally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC)Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma)Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)Locally advanced unresectable or metastatic colorectal cancer (CRC)2025-521702-18-00Novartis Pharma AG27
招募中
不适用
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors (CFML539A12101)Solid tumorjRCT20312602487
尚未招募
不适用
Phase I study of [225Ac]Ac-ETN029 in patients with advanced DLL3-expressing solid tumors (CESP359A12101)solid tumorjRCT20312602336
招募中
1 期
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients with Seropositive Rheumatoid ArthritisSeropositive Rheumatoid Arthritis2025-523265-15-00Candid Therapeutics Inc.9
尚未招募
不适用
BG-C137-101Advanced Solid TumorjRCT203125059119